Literature DB >> 19542319

Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.

Pari Malherbe1, Edilio Borroni, Emmanuel Pinard, Joseph G Wettstein, Frédéric Knoflach.   

Abstract

Recent preclinical and clinical research has shown that almorexant promotes sleep in animals and humans without disrupting the sleep architecture. Here, the pharmacology and kinetics of [(3)H]almorexant binding to human orexin 1 receptor (OX(1))- and human orexin 2 receptor (OX(2))-human embryonic kidney 293 membranes were characterized and compared with those of selective OX(1) and OX(2) antagonists, including 1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone (SB-674042), 1-(6,8-difluoro-2-methyl-quinolin-4-yl)-3-(4-dimethylamino-phenyl)-urea (SB-408124), and N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). The effect of these antagonists was also examined in vitro on the spontaneous activity of rat ventral tegmental area (VTA) dopaminergic neurons. [(3)H]Almorexant bound to a single saturable site on hOX(1) and hOX(2) with high affinity (K(d) of 1.3 and 0.17 nM, respectively). In Schild analyses using the [(3)H]inositol phosphates assay, almorexant acted as a competitive antagonist at hOX(1) and as a noncompetitive-like antagonist at hOX(2). In binding kinetic analyses, [(3)H]almorexant had fast association and dissociation rates at hOX(1), whereas it had a fast association rate and a remarkably slow dissociation rate at hOX(2). In the VTA, orexin-A potentiated the basal firing frequency to 175 +/- 17% of control in approximately half of the neurons tested. In the presence of 1 microM SB-674042 or SB-408124, the effect of orexin-A was only partially antagonized. However, in the presence of 1 microM EMPA or 1 microM almorexant, the effect of orexin-A was completely antagonized. In conclusion, almorexant exhibited a noncompetitive and long-lasting pseudo-irreversible mode of antagonism as a result of its very slow rate of dissociation from OX(2). The electrophysiology data suggest that OX(2) might be more important than OX(1) in mediating the effect of orexin-A on slow-firing of VTA dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542319     DOI: 10.1124/mol.109.055152

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

1.  Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.

Authors:  James R Shoblock; Natalie Welty; Leah Aluisio; Ian Fraser; S Timothy Motley; Kirsten Morton; James Palmer; Pascal Bonaventure; Nicholas I Carruthers; Timothy W Lovenberg; Jamin Boggs; Ruggero Galici
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 3.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

4.  Optogenetic identification of hypothalamic orexin neuron projections to paraventricular spinally projecting neurons.

Authors:  Olga Dergacheva; Akihiro Yamanaka; Alan R Schwartz; Vsevolod Y Polotsky; David Mendelowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-03       Impact factor: 4.733

5.  A food restriction protocol that increases drug reward decreases tropomyosin receptor kinase B in the ventral tegmental area, with no effect on brain-derived neurotrophic factor or tropomyosin receptor kinase B protein levels in dopaminergic forebrain regions.

Authors:  Y Pan; L Chau; S Liu; M V Avshalumov; M E Rice; K D Carr
Journal:  Neuroscience       Date:  2011-09-12       Impact factor: 3.590

6.  Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers.

Authors:  David A Perrey; Brian P Gilmour; Brian F Thomas; Yanan Zhang
Journal:  ACS Med Chem Lett       Date:  2014-03-25       Impact factor: 4.345

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 8.  An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.

Authors:  Kayla Janto; J Roxanne Prichard; Snigdha Pusalavidyasagar
Journal:  J Clin Sleep Med       Date:  2018-08-15       Impact factor: 4.062

Review 9.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

10.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.